Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Subscribe To Our Newsletter & Stay Updated
